CD44 and CD133 as cancer stem cell markers for gastric cancer

Journal of Gastric Cancer

Volumn 10, Issue 3, 2010, Pages 99-105

  Lee, Hyun Joo ^a   Choi, Young Sil ^a   Kim, Sung Joo ^a   Moon, Hyoun Jong ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Cancer stem cells; CD133; CD44; Gastric cancer

Indexed keywords

EID: 84867566253     PISSN: 2093582X     EISSN: 20935641     Source Type: Journal    
DOI: 10.5230/jgc.2010.10.3.99     Document Type: Article

References (28)

1. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells 1997;15(Suppl 1):199-203.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
3. Dick JE. Stem cells: self-renewal writ in blood. Nature 2003; 423:231-233.
4. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-1020.
5. Huang P, Wang CY, Gou SM, Wu HS, Liu T, Xiong JX. Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World J Gastroenterol 2008;14:3903-3907.
6. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009;568:161-173.
7. Ha TK, Kwon SJ. Clinicopathologic characteristics according to the type of recurrence in curtively-resected gastric cancer patients. J Korean Gastric Cancer Assoc 2007;7:23-30.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
9. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-110.
10. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-824.
11. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, et al. Cells with characteristics of cancer stem/pro genitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009;15:4299-4311.
12. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009;69:1776-1781.
13. Friedman S, Lu M, Schultz A, Thomas D, Lin RY. CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 2009;4:e5395.
14. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514.
15. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109.
16. Boegl M, Prinz C. CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009;100:1365-1366.
17. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008;118:2021-2024.
18. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-2120.
19. Hsieh HF, Yu JC, Ho LI, Chiu SC, Harn HJ. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol 1999;52:25-28.
20. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010;107:3722-3727.
21. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-765.
22. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancerinitiating cells from primary human tumors. Cancer Res 2008;68:4311-4320.
23. Yook JH, Choi WY, Shin DG, Kim YJ, Kim JS, Oh ST, et al. Expression of E-cardherin and CD44H in bormann type IV gastric cancer. J Korean Gastric Cancer Assoc 2004;4:82-88.
24. Mirecka J, Marx D, Schauer A. Immunohistochemical localization of CD44 variants 5 and 6 in human gastric mucosa and gastric cancer. Anticancer Res 1995;15:1459-1465.
25. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, et al. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010;101:673-678.
26. Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci 2009;100:1397-1402.
27. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-1957.
28. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009;125:2323-2331.